À propos

Jazz Pharmaceuticals plc (Nasdaq: JAZZ), is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases—often with limited or no options—so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again. Founded in 2003 and headquartered in Dublin, Ireland, Jazz Pharmaceuticals has a significant corporate presence in Palo Alto, CA and Philadelphia, PA and in England in London, Oxford and Cambridge, with manufacturing facilities in Ireland, England and Italy. We maintain a highly collaborative culture where employees focus on how they can be successful and accomplish positive results by exemplifying the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. Together, we are experts, analysts, specialists, advocates, scientists and professionals all with diverse backgrounds and perspectives. Working together, we are proud to support patients, innovate and bring new medicines to patients with critical unmet needs. Please see our website at www.jazzpharma.com for more information. For information on recruitment, please visit https://careers.jazzpharma.com/. For guidelines on engaging with Jazz on social media, please visit https://bit.ly/2OaMOuq.

Site web
http://www.jazzpharma.com
Secteur
Fabrication de produits pharmaceutiques
Taille de l’entreprise
1 001-5 000 employés
Siège social
Dublin
Type
Société cotée en bourse
Fondée en
2003
Domaines
Biopharmaceutical , innovation, research and development , great place to work, neuroscience , epilepsy, sleep disorders, oncology et hematology

Lieux

Employés chez Jazz Pharmaceuticals

Nouvelles

Pages similaires

Parcourir les offres d’emploi

Financement

Jazz Pharmaceuticals 6 rounds en tout

Dernier round

Dette après introduction en Bourse

1 500 000 000,00 $US

Voir plus d’informations sur Crunchbase